7-Fluoro-6-Nitroquinazolin-4(1H)-one CAS 162012-69-3 Purity >99.0% (HPLC) Afatinib Dimaleate Intermediate Factory

Short Description:

Chemical Name: 7-Fluoro-6-Nitroquinazolin-4(1H)-one 

CAS: 162012-69-3

Purity: >99.0% (HPLC) 

Yellow to Reddish Yellow Crystal or Powder

Intermediate of Afatinib Dimaleate (CAS: 850140-73-7)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name 7-Fluoro-6-Nitroquinazolin-4(1H)-one
Synonyms 7-Fluoro-6-Nitroquinazolin-4(3H)-one; 7-Fluoro-4-Hydroxy-6-Nitroquinazoline; 7-Fluoro-6-Nitroquinazolin-4-ol; 7-Fluoro-6-Nitro-4-Hydroxyquinazoline; 7-Fluoro-6-Nitro-1H-Quinazolin-4-one
CAS Number 162012-69-3
CAT Number RF-PI2025
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C8H4FN3O3
Molecular Weight 209.13
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Yellow to Reddish Yellow Crystal or Powder
1 H NMR Spectrum Consistent With Structure
Purity / Analysis Method >99.0% (HPLC)
Loss on Drying <0.50%
Total Impurities <1.00%
Proton NMR Spectrum Conforms to Structure
Test Standard Enterprise Standard
Usage Intermediate of Afatinib Dimaleate (CAS: 850140-73-7)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

7-Fluoro-6-Nitroquinazolin-4(1H)-one (CAS: 162012-69-3) is an intermediate of Afatinib Dimaleate (CAS: 850140-73-7). Afatinib is an irreversible ErbB family of blockers that suppress information transmission and block the major pathways involved in cancer cell growth and division. Because ErbB family information transduction mechanism can be triggered by multiple homodimers and heterodimers, simultaneous inhibition of multiple ErbB family members (such as EGFR, HER2, ErbB3 and ErbB4) can effectively interrupt the downstream information transduction. Afatinib is a drug approved for the treatment non-small cell lung carcinoma(NSCLC), developed by Boehringer Ingelheim. It acts as a angiokinase inhibitor. Like lapatinib and neratinib, afatinib is a tyrosine kinase inhibitor (TKI) that also irreversibly inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases. Afatinib is not only active against EGFR mutations targeted by first generation TKIs likeerlotinib or gefitinib, but also against those not sensitive to these standard therapies. Because of its additional activity against Her2, it is being investigated for breast cancer as well as other EGFR and Her2 driven cancers.

  • Write your message here and send it to us